EBS Emergent BioSolutions Inc
Emergent BioSolutions Inc (EBS) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $135.0K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Williams Paul Anthony | SVP, Products Business | Sell 10b5-1 | 3,000 | $8.40 | $25.2K | 159,098 −1.9% of holding | |
| Zoon Kathryn C 2 fills | Director | Sell 10b5-1 | 17,202 | $8.40 | $144.5K | 80,998 −17.5% of holding | |
| DeGolyer Donald W 2 fills | Director | Sell 10b5-1 | 15,481 | $8.40 | $130.0K | 130,675 −10.6% of holding | |
| Dayal Sujata Tyagi 2 fills | Director | Sell 10b5-1 | 13,761 | $8.40 | $115.6K | 101,543 −11.9% of holding | |
| Katkin Keith | Director | Sell 10b5-1 | 15,481 | $8.28 | $128.2K | 96,294 −13.9% of holding | |
| Williams Paul Anthony | SVP, Products Business | Sell 10b5-1 | 4,000 | $8.44 | $33.8K | 62,681 −6% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.